A carregar...
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
INTRODUCTION: Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key features of symptomatic chronic obstructive pulmonary disease (COPD). We assessed the effects of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on exercise tolerance in patien...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3430121/ https://ncbi.nlm.nih.gov/pubmed/22973092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S32451 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|